Pilar de la Puente

Exposure to chemotherapy alters secondary drug sensitivity without genomic alterations in patient-derived ovarian cancer organoid models

Ovarian cancer has significant morbidity and mortality due to high rates of resistance to chemotherapy and recurrence. Our objective was to deploy patient-derived organoid (PDO) models of ovarian cancer to assess secondary drug sensitivity after exposure to chemotherapy in vitro....